A judicial panel centralized several lawsuits filed against weight loss drugs like Ozempic and Wegovy, alleging that the medications failed to warn about potential gastrointestinal side effects.
On Friday, a U.S. judicial panel ruled that the various cases against pharma companies Novo Nordisk and Eli Lilly be centralized into a single multidistrict litigation (MDL). The cases were filed against three Novo Nordisk products—Ozempic, Wegovy, and Rybelsus—and two from Eli Lilly—Trulicity and Mounjaro. These products are GLP-1 receptor agonist (RA) drugs prescribed for treating type 2 diabetes and help certain obese or overweight individuals lose weight. Plaintiffs allege they suffered gastrointestinal injuries due to using the drugs, including gastroparesis, a condition in which a person’s stomach does not empty properly.
